Timothy Cody Ashby, MS, PhD

Associate Member

Research Program:

Cancer Biology

Faculty Rank:

Assistant Professor

Campus:

University of Arkansas for Medical Sciences

College:

College of Medicine

Department:

Biomedical Informatics

Cancer Research Interest

Disease Site Focus: Multiple Myeloma
Research Focus Area: Informatics
Type of Research: Population Sciences
Research Interest Statement: My primary research interest is in bioinformatics and cancer genomics. I have done analysis and implemented various algorithms on thousands of multiple myeloma samples across a variety of sequencing modalities such as targeted panel, reduced representation bisulfite, whole-genome, whole-exome, RNA, CHiP-Seq, Nanopore WGS, and 10X Genomics WGS.

Contact Information

Email Address: TCASHBY@UAMS.EDU
Profiles Research Networking Software: View Profile

Active Grants

NIH/Nat. Cancer Institute – 2R01CA209882
“Contribution of osteocytes to the musculoskeletal effects of Multiple Myeloma”
Co-Investigator
7/1/2023 – 6/30/2028

Recent Publications

Cheng Y, Sun F, Alapat DV, [et al., including Ashby C]. Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages. Blood cancer journal. 2024 14(1):194. PMID: 39505839. PMCID: PMC11541562.
Guo W, Strouse C, Mery D, [et al., including Ashby TC]. A Risk Stratification System in Myeloma Patients with Autologous Stem Cell Transplantation. Cancers. 2024 16(6). PMID: 38539451. PMCID: PMC10969019.
Sabol HM, Ashby C, Adhikari M, [et al.]. A NOTCH3-CXCL12-driven myeloma-tumor niche signaling axis promotes chemoresistance in multiple myeloma. Haematologica. 2024. PMID: 38385272. PMCID: PMC11290536.
Guo W, Zhan Y, Mery D, [et al., including Ashby TC]. Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems. Blood cancer journal. 2024 14(1):30. PMID: 38355688. PMCID: PMC10866867.
Sun F, Cheng Y, Wanchai V, [et al., including Ashby C]. Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth. Nature communications. 2024 15(1):615. PMID: 38242888. PMCID: PMC10798961.
Marino S, Petrusca DN, Bishop RT, [et al., including Ashby C]. Pharmacologic targeting of the p62 ZZ domain enhances both anti-tumor and bone-anabolic effects of bortezomib in multiple myeloma. Haematologica. 2023. PMID: 37981834. PMCID: PMC11063840.
Cheng Y, Sun F, Alapat DV, [et al., including Ashby C]. High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma. Cell reports. Medicine. 2023 4(10):101214. PMID: 37794587. PMCID: PMC10591052.
Sun F, Cheng Y, Ying J, [et al., including Ashby TC]. A gene signature can predict risk of MGUS progressing to multiple myeloma. Journal of hematology & oncology. 2023 16(1):70. PMID: 37386588. PMCID: PMC10308756.
Mohan M, Gong Z, Ashby TC, [et al.]. Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma. Cancer. 2023. PMID: 37282609.
Choudhury S, Byrum SD, Alkam D, [et al., including Ashby C]. Expression of integrin β-7 is epigenetically enhanced in multiple myeloma subgroups with high-risk cytogenetics. Clinical epigenetics. 2023 15(1):18. PMID: 36737807. PMCID: PMC9898982.
Bloedjes TA, de Wilde G, Khan GH, [et al., including Ashby TC]. AKT supports the metabolic fitness of multiple myeloma cells by restricting FOXO activity. Blood advances. 2022. PMID: 36322819. PMCID: PMC10182179.
Rasche L, Schinke C, Maura F, [et al., including Ashby C]. The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states. Nature communications. 2022 13(1):4517. PMID: 35922426. PMCID: PMC9349320.
Gai D, Chen JR, Stewart JP, [et al., including Ashby C]. CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation. The Journal of clinical investigation. 2022. PMID: 35881476. PMCID: PMC9479617.
Ashby C, Boyle EM, Bauer MA, [et al.]. Structural variants shape the genomic landscape and clinical outcome of multiple myeloma. Blood cancer journal. 2022 12(5):85. PMID: 35637217. PMCID: PMC9151656.
Sudha P, Ahsan A, Ashby C, [et al.]. Myeloma Genome Project Panel is a Comprehensive Targeted Genomics Panel for Molecular Profiling of Patients with Multiple Myeloma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2022. PMID: 35522533. PMCID: PMC9250632.
Bomken S, Enshaei A, Schwalbe EC, [et al., including Ashby C]. Molecular characterization and clinical outcome of B-cell precursor acute lymphoblastic leukemia with IG-MYC rearrangement. Haematologica. 2022. PMID: 35484682. PMCID: PMC9973471.
Sabol HM, Amorim T, Ashby C, [et al.]. Notch3 signaling between myeloma cells and osteocytes in the tumor niche promotes tumor growth and bone destruction. Neoplasia (New York, N.Y.). 2022 28:100785. PMID: 35390742. PMCID: PMC8990177.
Amawi H, Al-Azzam S, Alzanati T, [et al., including Ashby CR]. The Validity of Mobile Applications to Facilitate Patient Care Provided to Cancer Patients: Opportunities and Limitations. Recent patents on anti-cancer drug discovery. 2022 17(2):204-213. PMID: 34323199.
Mikulasova A, Kent D, Trevisan-Herraz M, [et al., including Ashby C]. Epigenomic translocation of H3K4me3 broad domains over oncogenes following hijacking of super-enhancers. Genome research. 2021. PMID: 34933939. PMCID: PMC9341503.
Roy Choudhury S, Ashby C, Zhan F, van Rhee F. Epigenetic Deregulation of Telomere-Related Genes in Newly Diagnosed Multiple Myeloma Patients. Cancers. 2021 13(24). PMID: 34944968. PMCID: PMC8699806.
Jones JR, Barber A, Le Bihan YV, [et al., including Ashby C]. Mutations in CRBN and other cereblon pathway genes are infrequently associated with acquired resistance to immunomodulatory drugs. Leukemia. 2021. PMID: 34373585. PMCID: PMC8478640.
Boyle EM, Rosenthal A, Ghamlouch H, [et al., including Ashby C]. Plasma cells expression from smouldering myeloma to myeloma reveals the importance of the PRC2 complex, cell cycle progression, and the divergent evolutionary pathways within the different molecular subgroups. Leukemia. 2021. PMID: 34365473.
Boyle EM, Rosenthal A, Wang Y, [et al., including Ashby C]. High-risk transcriptional profiles in multiple myeloma are an acquired feature that can occur in any subtype and more frequently with each subsequent relapse. British journal of haematology. 2021. PMID: 34244996.
Boyle EM, Williams L, Blaney P, [et al., including Ashby C]. Improving prognostic assignment in older adults with multiple myeloma using acquired genetic features, clonal hemopoiesis and telomere length. Leukemia. 2021. PMID: 34148053.
Li C, Xia J, Franqui Machin R, [et al., including Ashby TC]. TRIP13 modulates protein deubiquitination and accelerates tumor development and progression of B cell malignancies. The Journal of clinical investigation. 2021. PMID: 34061780. PMCID: PMC8279583.
Maura F, Boyle EM, Rustad EH, [et al., including Ashby C]. Chromothripsis as a pathogenic driver of multiple myeloma. Seminars in cell & developmental biology. 2021. PMID: 33958284.
Amawi H, Aljabali AAA, Boddu SHS, [et al., including Ashby CR Jr]. The use of zebrafish model in prostate cancer therapeutic development and discovery. Cancer chemotherapy and pharmacology. 2021 87(3):311-325. PMID: 33392639.
Wardell CP, Ashby C, Bauer MA. FiNGS: high quality somatic mutations using filters for next generation sequencing. BMC bioinformatics. 2021 22(1):77. PMID: 33602113. PMCID: PMC7890800.
Landau HJ, Yellapantula V, Diamond BT, [et al., including Ashby C]. Author Correction: Accelerated single cell seeding in relapsed multiple myeloma. Nature communications. 2021 12(1):591. PMID: 33473129. PMCID: PMC7817844.
Boyle EM, Deshpande S, Tytarenko R, [et al., including Ashby C]. The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma. Nature communications. 2021 12(1):293. PMID: 33436579. PMCID: PMC7804406.
Balaji S, Terrero D, Tiwari AK, [et al., including Ashby CR Jr]. Alternative approaches to overcome chemoresistance to apoptosis in cancer. Advances in protein chemistry and structural biology. 2021 126:91-122. PMID: 34090621.
Danziger SA, McConnell M, Gockley J, [et al., including Ashby C]. Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trials. PLoS medicine. 2020 17(11):e1003323. PMID: 33147277. PMCID: PMC7641353.
Rustad EH, Yellapantula VD, Glodzik D, [et al., including Ashby C]. Revealing the impact of structural variants in multiple myeloma. Blood cancer discovery. 2020 1(3):258-273. PMID: 33392515. PMCID: PMC7774871.
Deshpande S, Tytarenko RG, Wang Y, [et al., including Ashby C]. Monitoring treatment response and disease progression in myeloma with circulating cell-free DNA. European journal of haematology. 2020. PMID: 33107092.
Reznik SE, Tiwari AK, Ashby CR Jr. Edaravone: A potential treatment for the COVID-19-induced inflammatory syndrome?. Pharmacological research. 2020 160:105055. PMID: 32619723. PMCID: PMC7326414.
Choudhury SR, Ashby C, Tytarenko R, [et al.]. The functional epigenetic landscape of aberrant gene expression in molecular subgroups of newly diagnosed multiple myeloma. Journal of hematology & oncology. 2020 13(1):108. PMID: 32762714. PMCID: PMC7409490.
Landau HJ, Yellapantula V, Diamond BT, [et al., including Ashby C]. Accelerated single cell seeding in relapsed multiple myeloma. Nature communications. 2020 11(1):3617. PMID: 32680998. PMCID: PMC7368016.
Al-Oudat BA, Ramapuram H, Malla S, [et al., including Ashby CR Jr]. Novel Chrysin-De-Allyl PAC-1 Hybrid Analogues as Anticancer Compounds: Design, Synthesis, and Biological Evaluation. Molecules (Basel, Switzerland). 2020 25(13). PMID: 32635530. PMCID: PMC7412250.
Schinke C, Boyle EM, Ashby C, [et al.]. Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patterns. Blood cancer journal. 2020 10(6):70. PMID: 32555163. PMCID: PMC7303180.
Ashby C, Rutherford M, Bauer MA, [et al.]. TarPan: an easily adaptable targeted sequencing panel viewer for research and clinical use. BMC bioinformatics. 2020 21(1):144. PMID: 32293247. PMCID: PMC7158102.
Bauer MA, Ashby C, Wardell C, [et al.]. Differential RNA splicing as a potentially important driver mechanism in multiple myeloma. Haematologica. 2020. PMID: 32079689. PMCID: PMC7927887.
Boyle EM, Ashby C, Tytarenko R, [et al.]. BRAF and DIS3 Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020. PMID: 31988198.
Reznik SE, Tiwari AK, Ashby CR Jr. Potential Use of Sofosbuvir in the Prophylaxis for Rabies. Frontiers in pharmacology. 2020 11:472. PMID: 32322214. PMCID: PMC7156619.
Namdeo AG, Boddu SHS, Amawi H, [et al., including Ashby CR Jr]. Flavonoids as Multi-Target Compounds: A Special Emphasis on their Potential as Chemo-adjuvants in Cancer Therapy. Current pharmaceutical design. 2020 26(15):1712-1728. PMID: 32003663.
McIntosh K, Sarver J, Mell K, [et al., including Ashby CR Jr]. Oral and dermal toxicity of alkenones extracted from Isochrysis species. Frontiers in bioscience (Landmark edition). 2020 25(5):817-837. PMID: 31585919.